ABT: Bull Flag detected on 26 Aug 2026

ABT is forming a bull flag pattern with strong structural integrity (15.0/15 structure score) as the stock consolidates near all-time highs at $116.13. The pattern shows disciplined pullback behavior with support at $113.45 and resistance at $115.67, creating a tight flag range. Breakout score of 11.1 and volume ratio of 0.94 indicate slightly below-average volume during consolidation, but overall pattern quality is solid at 72.6/98. The setup benefits from strong recent momentum—up 11.14% in one month and 34.94% in three months—positioning for a measured move toward $119.96 on the breakout.

Wells Fargo maintained a Buy rating on Abbott on August 21, 2026, while Citi raised the price target to $125 from $112 on August 15, 2026. The company secured a $670 million settlement related to infant formula litigation and launched the Instinct glucose sensor paired with MiniMed's insulin pump, signaling progress on legal challenges and expansion in high-margin diabetes care. UBS issued a Buy rating citing strengthening nutrition franchise and 2026 growth drivers on July 28, 2026. These analyst upgrades and product launches are fueling the breakout environment. Healthcare sector remains in bullish regime (0.87 score), providing favorable tailwinds for the pattern to resolve higher.

A successful breakout above $115.67 resistance would target $119.96 conservatively, representing 3.3% upside from current levels. Historical bull flag patterns show 75.77% win probability, indicating favorable odds for northbound continuation. Volume confirmation is critical—traders should monitor for volume expansion above the 7.95M 20-day average during the breakout. The pattern invalidates decisively on a close below key support at $113.45, which would negate the bullish structure. RSI at 75.43 shows momentum is stretched, suggesting the breakout needs pullback confirmation rather than immediate continuation.

RSI at 75.43 signals overbought conditions, limiting near-term upside unless a consolidation occurs first. The stock trades 13.58% below its 52-week high of $134, meaning recent buyers are facing underwater positions and potential profit-taking. Volume ratio of 0.94 is below average, suggesting weak accumulation—breakout may not hold without volume surge. P/E multiple at 37.71 is elevated relative to historical ranges, leaving little margin for earnings disappointment. Beta of 0.45 is defensive, but the healthcare sector's strong regime (0.87) could reverse quickly if regulatory concerns around formula litigation resurface or if growth guidance disappoints in upcoming quarterly results. No imminent earnings date identified in search results, but dividend ex-date of July 15, 2026 has passed.

We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading.